Table 1.
Baseline Characteristics for the Intention-to-Treat Study Population
| Variable | WBRT + erlotinib (n = 106) | WBRT (n = 114) | P-value |
|---|---|---|---|
| n (%) | n (%) | ||
| Sex | |||
| Male | 63 (59.4) | 69 (60.5) | .869 |
| Female | 43 (40.6) | 45 (39.5) | |
| Age at random assignment, y | |||
| Median | 55.5 | 56.0 | .746 |
| Range | 26-70 | 27-70 | |
| Smoking status | |||
| Never | 62 (58.5) | 65 (57.0) | .717 |
| Current | 14 (13.2) | 12 (10.5) | |
| Former | 30 (28.3) | 37 (32.5) | |
| Pathological examination | |||
| Adenocarcinoma | 102 (96.2) | 103 (90.4) | .07 |
| Squamous carcinoma | 4 (3.8) | 6 (5.3) | |
| Adenosquamous carcinoma | 0 (0) | 3 (2.6) | |
| Others | 0 (0) | 2 (1.8) | |
| Neurological symptoms | |||
| Present | 63 (59.4) | 74 (64.9) | .236 |
| Absent | 43 (40.6) | 40 (35.1) | |
| EGFR status | |||
| Mutant | 58 (54.7) | 51 (44.7) | .001 |
| Negative | 48 (45.3) | 63 (55.3) | |
| Brain metastases, no. | |||
| ≤3 | 53 (50.0) | 48 (42.1) | .24 |
| >3 | 53 (50.0) | 66 (57.9) | |
| Extracranial metastases | |||
| Present | 59 (55.7) | 67 (58.8) | .641 |
| Absent | 47 (44.3) | 47 (41.2) | |
| Karnofsky performance status score | |||
| 70 | 19 (17.9) | 23 (20.2) | .409 |
| 80 | 62 (58.5) | 63 (55.3) | |
| 90 | 25 (23.6) | 26 (22.8) | |
| 100 | 0 (0) | 2 (1.7) | |
| GPA | |||
| 0.5 | 11 (10.4) | 13 (11.4) | .573 |
| 1 | 20 (18.9) | 23 (20.2) | |
| 1.5 | 24 (22.6) | 28 (24.5) | |
| 2 | 29 (27.4) | 23 (20.2) | |
| 2.5 | 13 (12.2) | 13 (11.4) | |
| 3 | 6(5.7) | 13(11.4) | |
| 3.5 | 3(2.8) | 1(0.9) |
Abbreviations: WBRT, whole-brain radiotherapy; EGFR, epithelial growth factor receptor; GPA, graded prognostic assessment.